Sugi Predict

Sugi Predict / Compounds / SCHEMBL3098734

SCHEMBL3098734

SCHEMBL3098734

Cc1cc(C(Oc2ccc(C(=O)N(C)CCC(=O)O)cc2)C2CCCCC2)c(C)o1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.37
▸ GCG P01275 3/20 0.37
▸ GCGR P47871 3/20 0.37
▸ ADCY1 Q08828 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ITGB3 P05106 1/20 0.34
▸ ITGA2B P08514 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ MITF O75030 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102074 0.90 KDM4E (0.36) KDM4ESMN1; SMN2NPC1HPGDRAB9A
SCHEMBL13093863 0.89 KDM4E (0.40) KDM4ESMN1; SMN2NPC1HPGDRAB9A
SCHEMBL3091354 0.88 MAPT (0.40) KDM4ENPC1HPGDRAB9A
SCHEMBL3091236 0.87 SLC6A9 (0.41) KDM4ESMN1; SMN2NPC1RAB9AGCGR
SCHEMBL3099764 0.87 ROCK2 (0.35) KDM4ESMN1; SMN2NPC1HPGDRAB9A
SCHEMBL3102778 0.87 MCHR1 (0.37) KDM4ESMN1; SMN2NPC1HPGDRAB9A
SCHEMBL3095027 0.87 ALDH1A1 (0.40) KDM4EHPGDRAB9AGCGGCGR
SCHEMBL3090571 0.85 NPC1 (0.38) KDM4ENPC1GCGGCGRKMT2A
SCHEMBL3102139 0.85 GCGR (0.46) GCGGCGRKMT2AMEN1
SCHEMBL3098966 0.85 GCGR (0.42) SMN1; SMN2NPC1HPGDRAB9AGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 — — EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 — — US disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 — — US disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 — — US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 — — US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 — — US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 — — US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR KDM4E 2280/4885SMN1; SMN2 4692/4885NPC1 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.